Proactive Investors - Run By Investors For Investors

Genetic Technologies executes agreement with Reprogenetics

Genetic Technologies executes agreement with Reprogenetics

Genetic Technologies (ASX: GTG; NASDAQ: GENE) has now executed a Settlement and License Agreement with Reprogenetics, U.S.

Genetic filed suit against Reprogenetics under its patent assertion program in late 2012.

With the execution of this agreement, Genetic has authorised the dismissal of legal action against Reprogenetics.

The commercial terms of the agreement are covered by formal confidentiality provisions and cannot be disclosed.

Genetic Technologies is a diagnostics company commercialising genetic testing, cancer diagnosis, non-coding DNA and product patenting throughout licensing.

Genetic's US subsidiary Phenogen’s lead product, BREVAGen™, is a first in class, clinically validated risk assessment test for non-familial breast cancer.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full GTG profile View Profile

Genetic Technologies Timeline

Newswire
March 06 2015

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
blood
December 04 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use